Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro that researchers study primarily as a peptide anxiolytic, that is, a compound with potential anti-anxiety activity. It is a stabilized analog of the natural immunomodulatory tetrapeptide tuftsin. If you are looking for what Selank is "for", the short honest answer is this: the main line of publications is an effect on anxiety and adaptation to stress, but the evidence base remains limited and mostly Russian-language, without large independent randomized clinical trials (RCTs). Below is what the real works actually show, what the documented regimen of use looked like in the studies, and why "reviews" should be treated with caution. Reference molecular data are collected in the Selank monograph, and the research form of the material is described on the Selank page.

The facts in brief

  • What it is: a synthetic heptapeptide, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP).
  • Origin: an analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg); the C-terminal Pro-Gly-Pro fragment increases the molecule's resistance to enzymatic breakdown.
  • Who developed it: the Institute of Molecular Genetics of the Russian Academy of Sciences together with a pharmacology school; registered in Russia as an intranasal medicine.
  • Line of study: anxiolytic (anti-anxiety) and nootropic activity.
  • State of the evidence: mostly preliminary studies and small samples; quality indexed RCTs are scarce.
  • Longeva: the material is supplied as research-use-only material and is not intended for human consumption.

What Selank is and why it is studied

Tuftsin is a natural four-amino-acid fragment of the immunoglobulin G molecule with immunomodulatory properties, but in its free form it is quickly broken down in the body. Selank was created as an "extended" and more stable version of tuftsin: the tripeptide Pro-Gly-Pro was added to the tetrapeptide core, which slows degradation and prolongs the biological action. That is why Selank is described in the literature both as an immunoactive and as a neurotropic compound.

The main research interest is focused on the anti-anxiety direction. In preclinical models (rodents), the peptide's effect on behavior under emotional stress, conflict models and active-avoidance reflexes was studied. The authors reported a modulatory rather than a sharply sedative profile, that is, a reduction in signs of anxiety without pronounced suppression. This distinguishes the presumed mechanism from classic benzodiazepines, although a direct transfer of results from rodents to humans is not valid.

A separate practical reason why Selank is studied specifically as an intranasal form is the biochemistry of the peptides themselves: short peptides survive the gastrointestinal tract poorly and are quickly broken down, so the oral route is ineffective for them. Intranasal administration bypasses this problem and theoretically helps the molecule reach central nervous system structures. This is a technological solution, not proof of clinical advantage, and it too should be read within the available, limited evidence base.

Mechanism of action: what the studies show

According to review and experimental works, Selank is credited with several interrelated directions of action:

  • GABA and serotonergic systems: modulation of inhibitory neurotransmission (GABA, gamma-aminobutyric acid) and serotonin metabolism is considered a probable basis of the anti-anxiety effect.
  • BDNF: in the hippocampus an increase in the level of brain-derived neurotrophic factor, a marker of neuroplasticity, has been described.
  • Enkephalin metabolism: the peptide affects the activity of enzymes that break down enkephalins, prolonging their action.
  • Monoamines and cytokines: changes in monoamine concentrations in the rodent brain and modulation of the cytokine balance (interleukin-6 in particular) were reported, which links the neurotropic and immune components.

It is important to understand the level of these data: most of the mechanistic conclusions were obtained in animal experiments or in laboratory models. The molecular aspects of the heptapeptide's biological activity are systematized in an English-language review in Protein & Peptide Letters (2018), one of the few indexed sources where the mechanism is described with references (see the "Sources" section). Structural details and a list of the studied targets are summarized in the Selank monograph.

Selank: what is known about the regimen of use from the research

Selank was studied mostly in the intranasal form; the documented regimens come from research reports, not from a guide for self-administration. We do not give the specific doses and frequency here, they are collected in the reference Selank: a regimen from a clinical report.

Selank: reviews or data? Why we do not publish anecdotes

Under the query "selank reviews" there are many subjective stories online. As a matter of principle we do not give invented reviews, "success stories" or effectiveness percentages, because that contradicts a research approach and is misleading. Anecdotal reviews, even sincere ones, do not replace controlled studies: they have no placebo control, no blinding, no standardized scales and no accounting for the expectation effect.

What can genuinely be said on the basis of published works: in small clinical and preclinical studies, anti-anxiety and anti-asthenic effects were observed with a profile more favorable than that of benzodiazepines in terms of sedation and dependence. But these are preliminary data of limited scope, mostly from one research circle and in one language. Independent Western replications and head-to-head comparisons with benzodiazepines in large RCTs are so far absent. So the correct framing is "a promising direction with an insufficient evidence base", not "a proven agent".

Safety, limitations and the status of the evidence

  • Limited evidence: most of the sources are preliminary, small, often Russian-language. Quality indexed RCTs are scarce; this should be directly taken into account in any conclusions.
  • Tolerability profile: in the available works the peptide was described as tolerated satisfactorily, but long-term safety data on large samples are lacking.
  • Regulatory status: Selank is registered as a medicine not in all jurisdictions; where it is available in a pharmacy, use is only on a physician's prescription.
  • Not medical advice: this material is informational and research in nature and is not a recommendation on diagnosis or treatment. The decision to use a registered medicine is made by a physician.

Researchers working with the peptide as a reagent should rely on certificates of analysis (purity, identity by MS (mass spectrometry)/HPLC (high-performance liquid chromatography, a method of purity testing)) and proper storage conditions; reference data are given in the Selank monograph, and the specification of the research form on the Selank page.